Stockscreener 앱 받기
0.8001
1.49%
-0.0121
시장 영업 전:
.80
-0.000100
-0.01%
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Weekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 notice - TradingView
Oncolytics Biotech Inc (ONCY) Balance Sheet - TradingKey
Oncolytics Biotech Inc (ONCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oncolytics Biotech Inc (ONCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.810|Chg%:-0.002 - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.812|Chg%:-0.036 - TradingKey
Oncolytics Biotech Inc. (ONCY) Files 8-K Notice of Nasdaq Delisting or Listing Rule Deficiency – July 2026 - Minichart
Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
ONCY Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech Inc (ONCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oncolytics (ONCY) Receives FDA Fast Track Designation for Pelare - GuruFocus
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Viral Immunotherapy Gets FDA Fast Track for Anal Cancer Patients Without Options - Tech Times
Oncolytics wins US FDA Fast Track for pelareorep in anal cancer - AllSci
FDA grants fast track status to Oncolytics’ anal cancer therapy By Investing.com - Investing.com South Africa
Oncolytics Biotech Gets US FDA Fast Track Designation for Pelareorep Combination in Anal Cancer Treatment - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Oncolytics receives FDA Fast Track for pelareorep plus checkpoint inhibitor in second-line+ anal cancer - TradingView
FDA grants fast track status to Oncolytics’ anal cancer therapy - Investing.com
Investigational anal cancer therapy posts 30% response rate - Stock Titan
Daily Brief Health Care: First Wave BioPharma , NeuroSpectrum Insights, Mesoblast Ltd, Know Labs , Zoetis Inc, CTT Pharmaceutical Holdings, Oncolytics Biotech, ATAI Life Sciences NV and more - Smartkarma
ONCY: Seeking Registration Pathway for Part B of REO 033 Trial - Smartkarma
MSN Money - MSN
Oncolytics Biotech (ONCY) Edges Lower Amid Light Trading – Key Levels in FocusSign of Weakness - dars.gov.et
Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer - Moomoo
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress - Investing.com UK
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress By Investing.com - Investing.com South Africa
Oncolytics advances colorectal cancer trial, plans FDA meeting - Investing.com UK
Oncolytics Biotech shares climb ahead of planned FDA meeting on REO 033 trial (ONCY) - MSN
Oncolytics advances colorectal cancer trial, plans FDA meeting By Investing.com - Investing.com South Africa
Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) - Yahoo Finance
Oncolytics (ONCY) Updates on REO 033 Clinical Study Progress - GuruFocus
Oncolytics Biotech stock jumps on FDA meeting plans for trial By Investing.com - Investing.com Canada
Oncolytics Biotech stock jumps on FDA meeting plans for trial - Investing.com
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial - The Manila Times
Oncolytics Biotech Announces Rapid REO 033 Site Activation and FDA Meeting on Registrational Pathway for Pelareorep in Metastatic Colorectal Cancer - Quiver Quantitative
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech Inc (ONCY) Institutional Confidence - TradingKey
Oncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1%What's Next? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Oncolytics Biotech Inc. Replaces Ernst & Young with Baker Tilly as Independent Auditor in 2026 Corporate Restructuring – Minichart - Minichart
Oncolytics Biotech (ONCY) replaces Ernst & Young with Baker Tilly as 2026 auditor - Stock Titan
NMAD Stock Price and Chart — NASDAQ:NMAD - TradingView
ONCY Should I Buy - Intellectia AI
1.97%
0.83%
자본화:
|
볼륨(24시간):